Glucagon-Like Peptide-1 Receptor agonists (GLP-1 RAs) may favorably affect CV risk through direct actions on the myocardium and blood vessels [61], and it has been shown that liraglutide may exert significant effects at the early stage of atherosclerosis and slows its progression [62]. Here, GLP1R is linked to atherosclerosis.